- What is Kratom?
- About Us
- Contact Us
- Log in
This week, we turn 1-year old! Celebrate with some of the hottest kratom deals, the latest kratom news headlines, and updates on what’s been happening here at Kratomaton.
On November 14th, 2018, the United States Food and Drug Administration issued Import Alert 66-41, a document that updates guidelines for the seizure of imported packages under the Detention Without Physical Examination (DWPE) protocol.
Although the FDA didn’t add any new flagged kratom sources within Import Alert 66-41, the update includes a change in terminology regarding “Unapproved New Drugs,” a category that has included kratom since 2012.
According to the document, the FDA now reserves the right to detain packages containing unapproved drugs via the appended statement:
Unapproved drugs present serious safety and effectiveness concerns.
When evidence exists for the marketing or promotion of unapproved drugs to individuals residing in the United States, the products should be considered for detention without physical examination.
Evidence of marketing or promotion may consist of information contained in: solicitations for mail orders; press releases; internet websites; advertising materials; label indications of US patents or patent applications; or other public announcements directed to persons residing in the U.S.
Now that the FDA has deemed any marketing or promotion of unapproved drugs as grounds for seizure, nearly all American kratom vendors who market themselves to fellow Americans could experience importation delays, resulting in reduced inventory and compromised order processing.
Already, these changes appear to have left many American kratom vendors short-handed, prompting turmoil within the larger American kratom community. Many American kratom users are wondering how this sudden surge in kratom import seizures will affect their country’s kratom economy in the coming months.
Unfortunately, only time will tell.
In a letter to the DEA, the United States Department of Health and Human Services recently advocated for the Schedule I classification of two of kratom’s primary psychoactive compounds – mitragynine and 7-hydroxymitragynine.
If passed, the recommendation would render these two kratom constituents as illicit and illegal on a federal level throughout the US.
Today, support for “fair” kratom regulation over total prohibition is arguably stronger than ever and is backed by visible organizations like the American Kratom Association and the Botanical Education Alliance. Still, it’s unclear how the DEA will respond to the HHS’ recommendation.
One year ago, on November 15th, 2017, Kratomaton went live! In fact, if you’re feeling nostalgic, you can view our inaugural blog post here.
Since our initial release, it’s been a pleasure to provide the online kratom community with information, aggregated user data, and broader perspectives on the dizzying array of kratom strains and online kratom vendors available.
Of course, none of this would have been possible without the interest and input of our users, so to all of you, thank you so much for your support!
We’ve added the following new vendors to our growing database of kratom sellers. Go check them out!
If you’d like to make a contribution to Kratomaton in the form of a donation, you can now do so here via PayPal or cryptocurrency. We appreciate your generosity!
Want to stay in the loop? Subscribe to our weekly newsletter and get regular updates on the latest kratom news, discounts, and more. It’s free and perhaps, more importantly, 100% spam-free!
Thank you for the continued support!